Impact of Eribulin Monotherapy on Post-Progression Survival in Patients with HER2-Negative Advanced or Metastatic Breast Cancer

While survival outcomes of early breast cancer cases have been improved remarkably in recent years, still many patients develop metastases and require the treatment against the relapsed disease. The 10-year survival rate of patients with advanced or metastatic breast cancer(A/MBC)is yet in the low level around 5%, despite the probability of disease silencing differs depending upon tumor subtype